Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* HER2-negative metastatic breast cancer~* candidates for taxane-based chemotherapy;~* ECOG performance status of 0 or 1.~Exclusion Criteria:~* previous chemotherapy for metastatic breast cancer;~* prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to study;~* prior radiotherapy for treatment of metastatic disease;~* chronic daily treatment with aspirin (325 mg/day) or clopidogrel(\>75mg/day).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin (bevacizumab) (Type: ACTIVE_COMPARATOR): None
- Avastin (bevacizumab) + Xeloda (capecitabine) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).